Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 15/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043889 | 0.91 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL6044169 | 0.87 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7428031 | 0.87 | HCAR3 (0.76) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL2248178 | 0.85 | HCAR3 (0.74) | HCAR3KMT2A | |
| SCHEMBL6044135 | 0.84 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL321911 | 0.83 | HCAR3 (1.00) | HCAR3MEN1KMT2ACASP6TSHR | |
| SCHEMBL6044279 | 0.83 | HCAR3 (1.00) | HCAR3MEN1KMT2A | |
| SCHEMBL5579612 | 0.83 | HCAR3 (0.70) | HCAR3MEN1KMT2A | |
| SCHEMBL6044265 | 0.82 | HCAR3 (0.78) | HCAR3CASP6 | |
| SCHEMBL9524361 | 0.82 | HCAR3 (0.69) | HCAR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119866333-A | KIT inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | 亚力维克希斯股份有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7402696-B2 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-7402696-B2 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20070105899-A1 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105899-A1 | Benzene compounds | AJINOMOTO CO., INC. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2004041274-A1 | BENZOTRIAZOLES AND METHODS OF PROPHYLAXIS OR TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HCAR3 186/4885MEN1 2447/4885KMT2A 3436/4885 |
| US-20060122240-A1 | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | GCGR, GPR119, HMGCR | HCAR3 85/4885MEN1 4692/4885KMT2A 2238/4885 |
| US-20070105899-A1 | Benzene compounds | ACACB, ACACA, FABP4 | HCAR3 1003/4885MEN1 4283/4885KMT2A 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.